Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).

医学 杜瓦卢马布 酪氨酸激酶 癌症研究 酪氨酸激酶抑制剂 内科学 肺癌 肿瘤科 非小细胞肺癌 间变性淋巴瘤激酶 病理 癌症 无容量 受体 免疫疗法 恶性胸腔积液 A549电池
作者
Ritujith Jayakrishnan,Amin H. Nassar,Frances A. Shepherd,Jessica J. Lin,Steven H. Lin,Purnima Shakya,Thomas J. Dilling,Jair Bar,Christian Grohé,Shruti Gupta,Bailey Fitzgerald,Elio Adib,K. Nathan Sankar,Joel W. Neal,Helena A. Yu,Ryan M. Whitaker,Ana I. Velazquez Mañana,Abdul Rafeh Naqash,Sarah B. Goldberg,So Yeon Kim
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 8013-8013
标识
DOI:10.1200/jco.2024.42.16_suppl.8013
摘要

8013 Background: For patients (pts) with unresectable locally-advanced NSCLC, standard of care involves durva consolidation after concurrent CRT, although its benefit in ALK+ tumors is unclear. The ALINA trial demonstrated adjuvant efficacy of alectinib in resected ALK+ NSCLC, but the optimal consolidation strategy for unresectable locally-advanced ALK+ NSCLC remains elusive. Methods: This multi-institutional international retrospective analysis included pts with stage III unresectable ALK+ NSCLC who received an ALK TKI, durva, or obs alone after concurrent CRT between 2015-2022. Baseline characteristics of age, sex, smoking history, and PD-L1 status were collected. Clinical outcomes including real-world progression-free survival (rw-PFS), overall survival (OS), and treatment-related adverse events (trAE) as defined using CTCAE 5.0 were assessed, and multivariate cox regression models were performed. Results: Sixty-four pts across 16 institutions were included. The median age was 57 (IQR 49-66) and 61% were females. The majority had adenocarcinoma (97%) and had never smoked (58%). 15 received ALK TKI (10 alectinib, 3 crizotinib, 1 brigatinib, 1 lorlatinib), 30 received durva, and 19 received obs alone. There was no significant difference in stage of cancer (IIIA, B, or C) or PD-L1 status among groups. After adjusting for stage and age at CRT initiation, median rw-PFS was significantly longer for ALK TKI (rw-PFS not reached [NR], 95% CI 22.7-NR) vs durva (11.3 months (mo), 95% CI 9.2-18.5, p= 0.005, HR = 0.12) or obs (7.4 mo, 95% CI 3.4-12.5, p < 0.0001). Two (13%) pts progressed on ALK TKI. 25 pts (83%) progressed on durva leading to treatment with ALK TKI in 23, and 18 (95%) progressed while under obs leading to treatment with ALK TKI in 15. 3-year OS was 100% for ALK TKI vs 90.5% for durva vs 63.5% for obs. Median OS was NR (95% CI NR-NR) for both ALK TKI and durva vs 70.6 mo (24.9-NR) in the obs group ( p= 0.03 for both ALK TKI and durva compared to obs). Median duration of therapy was 24.7 mo with ALK TKI and 6.5 mo with durva. Grade ≥3 trAE occurred in 27%, 7%, 6% of pts treated with ALK TKI (1 fatigue, 1 diarrhea, 1 hyperbilirubinemia, 1 pneumonitis), durva (1 fatigue, 1 neutropenia), and obs (1 neutropenia) respectively. Treatment discontinuation due to toxicity occurred in 4 (27%) with ALK TKI and in 3 (10%) with durva. Conclusions: In this retrospective study of stage III ALK+ NSCLC, consolidation ALK TKI demonstrated clinically meaningful improvement in PFS and OS over durva and obs, while showing a slightly higher rate of trAE over dura and obs. Furthermore, we show a high rate of progression following CRT alone in ALK+ NSCLC. These findings underscore the need for prospective molecularly driven trials to determine the optimal consolidation therapy for unresectable ALK+ NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科目三应助还单身的不二采纳,获得30
2秒前
yiyiyi完成签到,获得积分10
2秒前
眼睛大雨筠应助Candy采纳,获得50
2秒前
2秒前
Jasper应助嗯呐采纳,获得10
2秒前
情怀应助糖堆儿爱吃糖采纳,获得10
2秒前
2秒前
光亮若南完成签到,获得积分10
2秒前
CipherSage应助优雅狗采纳,获得10
3秒前
爱民完成签到,获得积分10
4秒前
李爱国应助TAC采纳,获得10
4秒前
孟双完成签到 ,获得积分20
4秒前
完美世界应助61forsci采纳,获得10
4秒前
含蓄绿兰发布了新的文献求助10
5秒前
5秒前
6秒前
汉堡包应助贾千兰采纳,获得10
6秒前
安静雅阳发布了新的文献求助10
6秒前
蝈蝈完成签到,获得积分10
6秒前
崔裕敬完成签到,获得积分20
6秒前
楼山柳发布了新的文献求助10
6秒前
7秒前
生椰拿铁不加生椰完成签到 ,获得积分10
7秒前
7秒前
7秒前
wzj完成签到,获得积分10
8秒前
仿生人发布了新的文献求助10
8秒前
万信心完成签到,获得积分10
9秒前
9秒前
10秒前
苏醒的记忆完成签到,获得积分10
10秒前
ZP完成签到 ,获得积分10
10秒前
可爱完成签到,获得积分10
10秒前
www完成签到,获得积分10
10秒前
10秒前
Dritsw应助clocksoar采纳,获得10
10秒前
12秒前
李健的小迷弟应助Loooong采纳,获得10
12秒前
。。发布了新的文献求助10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970724
求助须知:如何正确求助?哪些是违规求助? 3515419
关于积分的说明 11178342
捐赠科研通 3250592
什么是DOI,文献DOI怎么找? 1795372
邀请新用户注册赠送积分活动 875802
科研通“疑难数据库(出版商)”最低求助积分说明 805181